Cornerstone Advisory’s Viking Therapeutics VKTX Stock Holding History

Cornerstone Advisory’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-50	Closed	–	–	766
2021 Q4	$0	Buy	+50	New	+$280	﹤0.01%	846

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Cornerstone Advisory's VKTX Position: Q1 2022 in Review

Cornerstone Advisory sold out of Viking Therapeutics (VKTX) in Q1 2022, closing a stake of 50 shares.

Cornerstone Advisory first reported a position in VKTX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 140 funds tracked by Wall St. Rank hold VKTX as of Q1 2022.

Cornerstone Advisory reported no remaining Viking Therapeutics position as of Q1 2022 after selling out during the quarter.
Cornerstone Advisory sold 50 Viking Therapeutics shares in Q1 2022.
Cornerstone Advisory first reported a position in Viking Therapeutics in Q4 2021 and held it in 1 quarter.
Cornerstone Advisory's Viking Therapeutics position peaked at $0 in Q4 2021.
140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2022.

Based on Cornerstone Advisory's 13F filing for Q1 2022, filed 20 May 2022.